American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania

Bibliography

• LAVELLE F: American Association for Cancer Research1988: promises and prospects for the next century. Exp. Opin. Invest. Drugs (1998) 7:1015–1021.
   PubMedGoogle Scholar
• DANG CV, SEMENZA GL: Oncogenic alterations ofmetabolism. TIBS (1999) 24:68–72.
   PubMed Web of Science ®Google Scholar
• SCHELLENS JHM, DE KLERK G, SWART M et al.: Phase Iand pharmacological study with the novel farnesyl-transferase inhibitor ( FTO R155777. Proc. Am. Assoc. Cancer Res. (1999) 40:724: Abstract 4780.
   Google Scholar
• SOIGNET S, YAO SL, BRITTEN C et al: Pharmacokineticsand pharmacodynamics of the farnesyl protein transferase inhibitor (L-778,123) in solid tumors. Proc. Am. Assoc. Cancer Res. (1999) 40:517. Abstract 3413.
   Google Scholar
• ROSENBERG SH, ALDER J, BAUCH J et al: In vitro and invivo activity of the farnesyltransferase inhibitor A-197574. Proc. Am. Assoc. Cancer Res. (1999) 40:522. Abstract 3444.
   Google Scholar
• PREVOST GP, PRADINES A, VIOSSAT I et al: Inhibition ofin vitro and in vivo human cancer growth by a specific inhibitor of human farnesyl-transferase: BIM-46068. Proc. Am. Assoc. Cancer Res. (1999) 40:522. Abstract 3445.
   Google Scholar
• SKRZAT SG, BOWDEN CR, END DW: Interaction of thefarnesyl protein transferase inhibitor (FTO R115777 with cytotoxic chemotherapeutics in vitro and in vivo. Proc. Am. Assoc. Cancer Res. (1999) 40:523. Abstract 3447.
   Google Scholar
• VRIGNAUD P, BISSERY MC, MAILLIET et al: In vivocombination of RPR 130401, a non-peptidomimetic farnesyl transferase inhibitor, with chemotherapy. Proc. Am. Assoc. Cancer Res. (1999) 40:523 Abstract 3453.
   Google Scholar
• SHI B, GURNANI M, YAREMKO B et al: Enhancedefficacy of the farnesyl protein transferase inhibitor SCH 66336 in combination with paclitaxel. Proc. Am. Assoc. Cancer Res. (1999) 40:524. Abstract 3457.
   Google Scholar
• SMETS G, VAN EYCK N, DEVINE A et al.: R115777, aselective farnesyl transferase inhibitor (ETD, induces predominantly apoptotic activity in C39 melanoma tumor xenografts. Proc. Am. Assoc. Cancer Res. (1999) 40:522. Abstract 3446.
   Google Scholar
• BRASSARD DL, KIRSCHMEIER P, NAGABHUSHAN TL et al.:Proapoptotic effects of the farnesyl transferase inhibitor SCH 66336, on Ras-transformed Rat2 fibroblasts. Proc. Am. Assoc. Cancer Res. (1999) 40:524 Abstract 3455.
   Google Scholar
• IZBICKA E, LAWRENCE R, DAVIDSON K et al: Activity of afarnesyl transferase inhibitor (SCH 66336) against a broad range of tumors directly taken from patients. Proc. Am. Assoc. Cancer Res. (1999) 40:524. Abstract 3454.
   Google Scholar
• OMER CA, CHEN HY, CONNER MW et al: Inhibition oftumor growth in MMTV-Kirsten -ras (Val 12) transgenic mice with a farnesyl protein transferase inhibitor. Proc. Am. Assoc. Cancer Res. (1999) 40:523. Abstract 3449.
   Google Scholar
• LAVELLE F: American Association for Cancer Research: Progress and New Hope in the Fight against Cancer. Exp. Opin. Invest. Drugs (1997) 6:771–775.
   PubMedGoogle Scholar
• OGILVIE DJ, WEDGE SR, DUKES M et al: ZD 4190 : An orally administered inhibitor of VEGF signalling, with pan-xenograft antitumor activity. Proc. Am. Assoc. Cancer Res. (1999) 40:69. Abstract 458.
   Google Scholar
• VINCENT PW, PATMORE SJ, ATKINSON BE eta].: Optimal in vivo treatment schedule for the novel EGF receptor family tyrosine kinase inhibitor, PD 183805, correlates with the inhibition of the receptor tyrosine phosphorylation. Proc. Am. Assoc. Cancer Res. (1999) 40:117 Abstract 776.
   Google Scholar
• PATMORE SJ, ATKINSON BA, BRADFORD LA eta].: In vivoactivity of the broadly active tyrosine kinase inhibitor PD166285. Proc. Am. Assoc. Cancer Res. (1999) 40:723. Abstract 4779.
   Google Scholar
• SHAWVER LK, STRAWM LM, FONG TAT et al. SU6668 is a potent, broad spectrum angiogenesis inhibitor that exhibits anti-tumor properties. Proc. Am. Assoc. Cancer Res. (1999) 40:723 Abstract 4777.
   Google Scholar
• SAUSVILLE EA, KAUR G, WORLAND P et al: Cyclin-dependent kinases as novel targets for therapy. Proc. Am. Assoc. Cancer Res. (1999) 40:764–765.
   Google Scholar
• WALKER DH, LUZZIO M, VEAL J et al.: The novel cyclic dependent kinase inhibitors, GW 5181 and GW 9499 regulate cell cycle progression and induce tumor-selective cell death. Proc. Am. Assoc. Cancer Res. (1999) 40:724. Abstract 4783.
   Google Scholar
• HAUSHEER F, CAO S, KANTER P et al.: Karenitecins: New preclinical developments with BNP-1350 a novel, potent highly lipophilic camptothecin. Proc. Am. Assoc. Cancer Res. (1999) 40:111. Abstract 741.
   Google Scholar
• KASPRZYK PG, DEMARQUAY D, LESUERU-GINOT L et al.: An E-ring modified camptothecin, BM-80915, shows unusual stability and high activity both in vitro and in vivo. Proc. Am. Assoc. Cancer Res. (1999) 40:111. Abstract 739.
   Google Scholar
• HILL BT, BARRET JM, PERRIN D et al: Mechanism of action of F 11782, a novel catalytic dual inhibitor of topoisomerases I and II. Proc. Am. Assoc. Cancer Res. (1999) 40:114 Abstract 755.
   Google Scholar
• PRATESI G, POLIZZI D, TORTORETO M et al.: IDN 5109, a new taxane active after oral administration. Proc. Am. Assoc. Cancer Res. (1999) 40:287. Abstract 1905.
   Google Scholar
• BACHER G, HOXTER M, EMIG P et al: D-24851, a small molecule, destabilizes microtubules. Proc. Am. Assoc. Cancer Res. (1999) 40:285. Abstract 1893.
   Google Scholar
• ZHANG XG, TAN QH, CHEN LI et al: Desoxyepothilone B (dEpoB): A tubulin stabilizing macrolide, is curative against human tumor xenografts that are refractory to taxol. Proc. Am. Assoc. Cancer Res. (1999) 40:287. Abstract 1906.
   Google Scholar
• LUKE RWA, HUDSON K, HAYWARD CF et al.: Design andsynthesis of small molecule inhibitors of the MDM2-p53 interaction as potential anti-tumor agents. Proc. Am. Assoc. Cancer Res. (1999) 40:622. Abstract 4099.
   Google Scholar
• MITSUNOBU H, TAKAHUKI N, MASAYUKI M et al.: Tetrocarcin A inhibits anti-apototic function of bc1-2. Proc. Am. Assoc. Cancer Res. (1999) 40:622. Abstract 4100.
   Google Scholar
• SCRIVENS PJ, POSNER B, SHAVER A et al.: PeroxoVana-dium compounds : Potent inhibitors of a rationale target for chemotherapy, the CDC25 family of dual-specificity phosphatases. Proc. Am. Assoc. Cancer Res. (1999) 40:622. Abstract 4103.
   Google Scholar
• SACKETT DL, BATES SE, ROBBINS AR: Histone deacety-lase inhibitors induce mitotic arrest in human cancer cells, disrupting kinetochores and centrosomes. Proc. Am. Assoc. Cancer Res. (1999) 40:623. Abstract 4106. Francois Lavelle Rhone-Poulenc Rorer, Centre de Recherche de Vitry-Alfortville, 94403 Vitry -sur-Seine Cedex, France
   Google Scholar